IL131957A - Stable complexes of poorly soluble compounds - Google Patents
Stable complexes of poorly soluble compoundsInfo
- Publication number
- IL131957A IL131957A IL13195799A IL13195799A IL131957A IL 131957 A IL131957 A IL 131957A IL 13195799 A IL13195799 A IL 13195799A IL 13195799 A IL13195799 A IL 13195799A IL 131957 A IL131957 A IL 131957A
- Authority
- IL
- Israel
- Prior art keywords
- poorly soluble
- soluble compounds
- stable complexes
- complexes
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10133698P | 1998-09-22 | 1998-09-22 | |
US13653199P | 1999-05-28 | 1999-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL131957A0 IL131957A0 (en) | 2001-03-19 |
IL131957A true IL131957A (en) | 2005-06-19 |
Family
ID=26798138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13195799A IL131957A (en) | 1998-09-22 | 1999-09-16 | Stable complexes of poorly soluble compounds |
Country Status (33)
Country | Link |
---|---|
US (1) | US6350786B1 (da) |
EP (1) | EP0988863B2 (da) |
JP (5) | JP2000095708A (da) |
KR (1) | KR100362019B1 (da) |
CN (1) | CN1201821C (da) |
AR (2) | AR022096A1 (da) |
AT (1) | ATE265232T1 (da) |
AU (1) | AU770745B2 (da) |
BR (1) | BR9904283A (da) |
CA (1) | CA2282906C (da) |
CO (1) | CO5140077A1 (da) |
CZ (1) | CZ300215B6 (da) |
DE (1) | DE69916733T3 (da) |
DK (1) | DK0988863T4 (da) |
ES (1) | ES2218918T5 (da) |
HK (1) | HK1026632A1 (da) |
HR (1) | HRP990287B1 (da) |
HU (1) | HU228341B1 (da) |
ID (1) | ID24034A (da) |
IL (1) | IL131957A (da) |
MA (1) | MA26692A1 (da) |
MY (1) | MY124377A (da) |
NO (1) | NO326928B1 (da) |
NZ (1) | NZ337884A (da) |
PE (1) | PE20001049A1 (da) |
PL (1) | PL202757B1 (da) |
PT (1) | PT988863E (da) |
RS (1) | RS50193B (da) |
RU (1) | RU2240827C2 (da) |
SG (1) | SG97131A1 (da) |
SI (1) | SI0988863T2 (da) |
TR (1) | TR199902324A3 (da) |
TW (1) | TWI234465B (da) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60039379D1 (de) | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
CO5210860A1 (es) * | 1999-10-01 | 2002-10-30 | Hoffmann La Roche | Nuevos derivados de pirimidina-2,4,6-triona |
US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
DK1301221T3 (da) * | 2000-05-16 | 2006-07-03 | Ortho Mcneil Pharm Inc | Fremgangsmåde til overtrækning af medicinske artikler ved anvendelse af superkritisk carbondioxid |
US6469179B1 (en) | 2000-10-03 | 2002-10-22 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US6482847B2 (en) | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US6716845B2 (en) * | 2001-03-30 | 2004-04-06 | Hoffmann-La Roche Inc. | Barbituric acid derivatives |
DE10296849T5 (de) * | 2001-05-30 | 2004-04-29 | Csir Corporate Building Scientia | Verfahren zur Einkapselung eines Wirkstoffes |
US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
WO2002102373A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for administration of cancer therapeutic |
ATE444060T1 (de) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
JP2004534822A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 低溶解度および/または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物 |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
EP1429749A2 (en) | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20030139373A1 (en) * | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
BR0307333A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização |
EP1530457B1 (en) | 2002-08-12 | 2009-09-09 | Bend Research, Inc. | Pharmaceutical compositions of drugs in semi-ordered form and polymers |
DE10351087A1 (de) * | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
JP4947482B2 (ja) * | 2003-11-14 | 2012-06-06 | 味の素株式会社 | フェニルアラニン誘導体の徐放性経口投与製剤 |
WO2005046696A1 (ja) | 2003-11-14 | 2005-05-26 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤 |
CN1950110B (zh) * | 2004-04-01 | 2012-11-21 | 列日大学 | 嘧啶-2,4,6-三酮的药物组合物 |
AR049915A1 (es) * | 2004-06-14 | 2006-09-13 | Anacor Pharmaceuticals Inc | Compuestos con contenido de boro y metodos de uso de los mismos |
WO2006062980A2 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising tiagabine |
US20080063710A1 (en) * | 2004-12-28 | 2008-03-13 | Eisai R&D Management Co., Ltd. | Rapidly Disintegrating Tablet and Production Method Thereof |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CA2605214C (en) | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
EP1690528A1 (de) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs |
WO2006123223A1 (en) * | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
RS52010B (en) * | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
US20080031944A1 (en) * | 2006-08-04 | 2008-02-07 | Cima Labs Inc. | Stabilization of lorazepam |
CL2007002331A1 (es) * | 2006-08-10 | 2008-04-18 | Cipla Ltd | Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih. |
US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
JPWO2008081829A1 (ja) * | 2006-12-27 | 2010-04-30 | アステラス製薬株式会社 | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe |
CN101702878B (zh) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
EP1997479A1 (en) * | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009052391A1 (en) * | 2007-10-19 | 2009-04-23 | Purdue Research Foundation | Solid formulations of crystalline compounds |
US7794750B2 (en) * | 2008-06-20 | 2010-09-14 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US8632805B2 (en) * | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US20100099696A1 (en) * | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
KR20100073454A (ko) * | 2008-12-23 | 2010-07-01 | 국립암센터 | 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
EP2414356B1 (en) * | 2009-04-03 | 2015-09-02 | F.Hoffmann-La Roche Ag | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
CN106220623A (zh) | 2009-11-06 | 2016-12-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
JPWO2011152297A1 (ja) * | 2010-05-31 | 2013-08-01 | アステラス製薬株式会社 | トリアゾール化合物の固体分散体 |
EA028821B9 (ru) | 2011-02-07 | 2018-10-31 | Плексксикон, Инк. | Соединения и способы для модуляции киназ, а также показания к их применению |
RU2013139701A (ru) | 2011-02-17 | 2015-03-27 | Ф. Хоффманн-Ля Рош Аг | Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
EP2744803A2 (en) | 2011-08-18 | 2014-06-25 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors |
WO2013037396A1 (en) * | 2011-09-12 | 2013-03-21 | Bioneer A/S | Solution of polymer in api for a solid dosage form |
JP6140168B2 (ja) | 2011-09-27 | 2017-05-31 | ドクター レディズ ラボラトリーズ リミテッド | アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体 |
SI2765990T1 (sl) * | 2011-10-14 | 2017-11-30 | Array Biopharma, Inc. | Trdna disperzija |
SI3400943T1 (sl) * | 2012-03-23 | 2021-03-31 | Array Biopharma, Inc. | Spojine za uporabo pri zdravljenju možganskih metastaz pri bolniku z ErbB2+ rakom dojke |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JO3339B1 (ar) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه |
CN104918608A (zh) | 2012-11-19 | 2015-09-16 | 雷迪博士实验室有限公司 | Cetp抑制剂的药物组合物 |
CN105007899A (zh) * | 2012-12-20 | 2015-10-28 | 卡希夫制药有限责任公司 | 用于提高生物利用度的口腔崩解片制剂 |
EP2948141A1 (en) | 2013-01-22 | 2015-12-02 | F. Hoffmann-La Roche AG | Pharmaceutical composition with improved bioavailability |
TWI615157B (zh) | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
US20160213575A1 (en) * | 2013-09-11 | 2016-07-28 | 3M Innovative Properties Company | Coating compositions, dental structures thereof and methods for generating contrast |
JP6505705B2 (ja) * | 2013-12-05 | 2019-04-24 | アルライズ バイオシステムズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 経口投与用製剤の製造方法 |
PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
MX2017015322A (es) * | 2015-05-29 | 2018-03-28 | Sun Pharmaceutical Ind Ltd | Composicion farmaceutica oral de isotretinoin. |
BR112019008295B1 (pt) | 2016-12-13 | 2024-03-12 | TransThera Sciences (Nanjing), Inc | Composto inibidor de multiquinase, forma cristalina do composto de fórmula iii, formulação/composição farmacêutica, seus usos, métodos para a preparação da forma cristalina e do composto de fórmula iii e intermediário para a preparação do composto de fórmula iii |
JP7328151B2 (ja) | 2017-04-28 | 2023-08-16 | シージェン インコーポレイテッド | Her2陽性がんの処置 |
KR102082775B1 (ko) * | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 조성물 |
RU2725879C2 (ru) * | 2018-07-26 | 2020-07-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов |
JP2022509965A (ja) | 2018-12-03 | 2022-01-25 | ハー・ルンドベック・アクチエゼルスカベット | 4-((1R,3S)-6-クロロ-3-フェニル-2,3-ジヒドロ-1H-インデン-1-イル)-1,2,2-トリメチルピペラジン及び4-((1R,3S)-6-クロロ-3-(フェニル-d5)-2,3-ジヒドロ-1H-インデン-1-イル)-2,2-ジメチル-1-(メチル-d3)ピペラジンのプロドラッグ |
AU2021210974A1 (en) | 2020-01-24 | 2022-09-22 | Nanocopoeia, Llc | Amorphous solid dispersions of dasatinib and uses thereof |
CA3168680A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
US20230118965A1 (en) | 2020-03-03 | 2023-04-20 | Dexerials Corporation | Method for manufacturing image display device |
CA3181361A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
US11980619B2 (en) | 2021-07-28 | 2024-05-14 | Nanocopoeia, Llc | Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
AU6569886A (en) * | 1985-11-27 | 1987-06-04 | Syntex (U.S.A.) Inc. | Amorphous benzimidazole anthelminitics |
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
JP2528706B2 (ja) † | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
USRE36736E (en) | 1989-02-06 | 2000-06-13 | Hoffman-La Roche Inc. | Substituted pyrroles |
JPH0729926B2 (ja) † | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | 易吸収性製剤用組成物 |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
ES2111065T5 (es) † | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
TW493991B (en) | 1995-05-08 | 2002-07-11 | Novartis Ag | Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same |
GB9511220D0 (en) † | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
PT784974E (pt) * | 1995-07-26 | 2003-09-30 | Kyowa Hakko Kogyo Kk | Preparacao de derivados de xantina numa dispersao solida |
WO1997008950A1 (en) † | 1995-09-07 | 1997-03-13 | Fuisz Technologies, Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
DE19548624A1 (de) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
JPH09208459A (ja) * | 1996-02-07 | 1997-08-12 | Eisai Co Ltd | 溶解性を改良した製剤 |
PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
DE69730241T2 (de) * | 1996-06-28 | 2005-08-11 | Schering Corp. | Feste lösung eines fungizids mit erhöhter bioverfügbarkeit |
PE91598A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
ATE243693T1 (de) | 1998-03-17 | 2003-07-15 | Hoffmann La Roche | Substituierte bisindolylmaleimide zur inhibierung der zellproliferation |
-
1999
- 1999-09-07 US US09/391,060 patent/US6350786B1/en not_active Expired - Lifetime
- 1999-09-13 SI SI9930573T patent/SI0988863T2/sl unknown
- 1999-09-13 ES ES99117908T patent/ES2218918T5/es not_active Expired - Lifetime
- 1999-09-13 EP EP99117908A patent/EP0988863B2/en not_active Expired - Lifetime
- 1999-09-13 DK DK99117908T patent/DK0988863T4/da active
- 1999-09-13 DE DE69916733T patent/DE69916733T3/de not_active Expired - Lifetime
- 1999-09-13 PT PT99117908T patent/PT988863E/pt unknown
- 1999-09-13 AT AT99117908T patent/ATE265232T1/de active
- 1999-09-16 IL IL13195799A patent/IL131957A/xx not_active IP Right Cessation
- 1999-09-17 CZ CZ0330499A patent/CZ300215B6/cs not_active IP Right Cessation
- 1999-09-17 SG SG9904570A patent/SG97131A1/en unknown
- 1999-09-17 NZ NZ337884A patent/NZ337884A/xx not_active IP Right Cessation
- 1999-09-17 PE PE1999000947A patent/PE20001049A1/es not_active IP Right Cessation
- 1999-09-17 CO CO99059117A patent/CO5140077A1/es unknown
- 1999-09-20 CA CA2282906A patent/CA2282906C/en not_active Expired - Lifetime
- 1999-09-20 HR HR990287 patent/HRP990287B1/xx not_active IP Right Cessation
- 1999-09-20 HU HU9903189A patent/HU228341B1/hu unknown
- 1999-09-20 MY MYPI99004065A patent/MY124377A/en unknown
- 1999-09-20 AU AU48807/99A patent/AU770745B2/en not_active Expired
- 1999-09-20 ID IDP990878D patent/ID24034A/id unknown
- 1999-09-20 AR ARP990104725A patent/AR022096A1/es not_active Application Discontinuation
- 1999-09-20 TW TW088116184A patent/TWI234465B/zh not_active IP Right Cessation
- 1999-09-21 NO NO19994583A patent/NO326928B1/no not_active IP Right Cessation
- 1999-09-21 RU RU99120377/15A patent/RU2240827C2/ru active
- 1999-09-21 RS YUP-473/99A patent/RS50193B/sr unknown
- 1999-09-21 JP JP11267142A patent/JP2000095708A/ja not_active Withdrawn
- 1999-09-21 CN CNB991194063A patent/CN1201821C/zh not_active Expired - Lifetime
- 1999-09-21 TR TR1999/02324A patent/TR199902324A3/tr unknown
- 1999-09-21 BR BR9904283-5A patent/BR9904283A/pt not_active Application Discontinuation
- 1999-09-21 MA MA25778A patent/MA26692A1/fr unknown
- 1999-09-22 PL PL335592A patent/PL202757B1/pl unknown
- 1999-09-22 KR KR1019990041130A patent/KR100362019B1/ko active IP Right Grant
-
2000
- 2000-09-19 HK HK00105891A patent/HK1026632A1/xx not_active IP Right Cessation
-
2007
- 2007-06-06 JP JP2007150911A patent/JP2007224048A/ja active Pending
-
2011
- 2011-04-13 AR ARP110101253A patent/AR080892A2/es not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230446A patent/JP6253135B2/ja not_active Expired - Lifetime
-
2015
- 2015-07-16 JP JP2015141952A patent/JP2015187170A/ja active Pending
-
2016
- 2016-08-31 JP JP2016169245A patent/JP6534979B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL131957A (en) | Stable complexes of poorly soluble compounds | |
HRP20000381B1 (en) | Stable complexes of poorly soluble compounds | |
AU4580599A (en) | Stable no-delivering compounds | |
IL126546A0 (en) | Inclusion complexes of aryl-heterocyclic salts | |
GB9711237D0 (en) | Organomettallic Complexes | |
HUP0103349A3 (en) | Phthalazine derivatives as phosphodiesterase 4 inhibitors | |
GB9817118D0 (en) | Pharmaceutical compounds | |
GB2357761B (en) | Compounds | |
HUP0202477A3 (en) | Use of phthalazine derivatives | |
PL347324A1 (en) | Bridged metal complexes | |
GB9817623D0 (en) | Pharmaceutical compounds | |
GB9810886D0 (en) | Pharmaceutical compounds | |
IL139490A0 (en) | Phthalazine derivatives as phosphodiesterase 4 inhibitors | |
AU5047399A (en) | Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition | |
AU3632400A (en) | Metal complexes containing bridging heteroatom for olefin-polymerization-process | |
GB9800750D0 (en) | Pharmaceutical compound | |
AU1488001A (en) | Stabilized thyroxine compounds | |
GB9823847D0 (en) | Pharmaceutical compounds | |
AU4222599A (en) | Poly-oxyanions as anchoring agents for metal complexes | |
GB9823845D0 (en) | Pharmaceutical compounds | |
ZA996045B (en) | Stable complexes of poorly soluble compounds. | |
AU3739300A (en) | Synthesis of vapol ligands | |
GB9817197D0 (en) | Pharmaceutical compounds | |
GB9803605D0 (en) | Schiffs base complexes | |
GB9810855D0 (en) | Use of compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |